{"<h3>Importance</h3>": [0], "Pancreatic": [1], "ductal": [2], "adenocarcinoma": [3], "(PDAC)": [4], "is": [5, 26, 36, 51, 74, 174, 203, 266, 306], "a": [6, 131, 231, 241, 259, 267], "relatively": [7], "uncommon": [8], "cancer,": [9], "with": [10, 60, 113, 124, 135, 145, 165, 187, 213, 240, 251], "approximately": [11, 293], "60": [12, 282], "430": [13], "new": [14, 284], "diagnoses": [15], "expected": [16], "in": [17, 19], "2021": [18], "the": [20, 40, 96, 107, 245], "US.": [21], "The": [22, 302], "incidence": [23, 303], "of": [24, 43, 98, 106, 141, 234, 249, 286, 295, 304], "PDAC": [25, 287, 305], "increasing": [27], "by": [28, 46, 103, 121, 170, 201], "0.5%": [29], "to": [30, 38, 194, 236, 247], "1.0%": [31], "per": [32, 290], "year,": [33, 291], "and": [34, 56, 84, 89, 100, 181, 190, 217, 226, 255, 279, 292, 326], "it": [35], "projected": [37], "become": [39], "second-leading": [41], "cause": [42], "cancer-related": [44], "mortality": [45], "2030.": [47], "<h3>Observations</h3>": [48], "Effective": [49], "screening": [50], "not": [52], "available": [53, 309], "for": [54, 148, 154, 172, 179, 206, 312], "PDAC,": [55, 219, 257], "most": [57], "patients": [58, 112, 186, 212, 250, 296], "present": [59], "locally": [61, 90, 188], "advanced": [62, 91, 189, 214, 216, 298, 313], "(30%-35%)": [63], "or": [64, 166], "metastatic": [65, 256], "(50%-55%)": [66], "disease": [67, 93, 115, 192, 209, 299, 314], "at": [68, 116, 300], "diagnosis.": [69, 301], "A": [70], "multidisciplinary": [71, 321], "management": [72], "approach": [73, 134, 178], "recommended.": [75, 331], "Localized": [76], "pancreas": [77], "cancer": [78], "includes": [79], "resectable,": [80], "borderline": [81, 182], "resectable": [82, 114, 180, 183], "(localized": [83], "involving": [85], "major": [86], "vascular": [87, 196], "structures),": [88], "(unresectable)": [92], "based": [94], "on": [95], "degree": [97], "arterial": [99], "venous": [101], "involvement": [102], "tumor,": [104], "typically": [105], "superior": [108], "mesenteric": [109], "vessels.": [110], "For": [111, 185, 211, 244, 318], "presentation": [117], "(10%-15%),": [118], "surgery": [119, 173], "followed": [120, 169, 200], "adjuvant": [122], "chemotherapy": [123, 221], "FOLFIRINOX": [125], "(fluorouracil,": [126], "irinotecan,": [127], "leucovorin,": [128], "oxaliplatin)": [129], "represents": [130], "standard": [132], "therapeutic": [133], "an": [136, 175, 204], "anticipated": [137], "median": [138], "overall": [139], "survival": [140, 232, 273], "54.4": [142], "months,": [143], "compared": [144, 239], "35": [146], "months": [147, 238], "single-agent": [149, 242], "gemcitabine": [150], "(stratified": [151], "hazard": [152], "ratio": [153], "death,": [155], "0.64": [156], "[95%": [157], "CI,": [158], "0.48-0.86];<i>P</i>": [159], "=": [160], ".003).": [161], "Neoadjuvant": [162], "systemic": [163, 198], "therapy": [164, 199], "without": [167], "radiation": [168, 202], "evaluation": [171], "accepted": [176], "treatment": [177], "disease.": [184], "unresectable": [191], "due": [193], "extensive": [195], "involvement,": [197], "option": [205, 269], "definitive": [207], "locoregional": [208], "control.": [210], "(locally": [215], "metastatic)": [218], "multiagent": [220], "regimens,": [222], "including": [223], "FOLFIRINOX,": [224], "gemcitabine/nab-paclitaxel,": [225], "nanoliposomal": [227], "irinotecan/fluorouracil,": [228], "all": [229, 319], "have": [230, 297], "benefit": [233], "2": [235], "6": [237], "gemcitabine.": [243], "5%": [246], "7%": [248], "a<i>BRCA</i>pathogenic": [252], "germline": [253, 324], "variant": [254], "olaparib,": [258], "poly": [260], "(adenosine": [261], "diphosphate": [262], "[ADB]-ribose)": [263], "polymerase": [264], "inhibitor,": [265], "maintenance": [268], "that": [270], "improves": [271], "progression-free": [272], "following": [274], "initial": [275], "platinum-based": [276], "therapy.": [277], "<h3>Conclusions": [278], "Relevance</h3>": [280], "Approximately": [281], "000": [283], "cases": [285], "are": [288, 315, 330], "diagnosed": [289], "50%": [294], "increasing.": [307], "Currently": [308], "cytotoxic": [310], "therapies": [311], "modestly": [316], "effective.": [317], "patients,": [320], "management,": [322], "comprehensive": [323], "testing,": [325], "integrated": [327], "supportive": [328], "care": [329]}